Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 8026 - 8050 of 8610 in total
Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Investigational
Matched Description: … Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of
mRNA-3705 is an investigational mRNA encoding methylmalonic CoA mutase (MUT) enzyme. Developed by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.
Investigational
Matched Description: … ., it is being investigated for the treatment of methylmalonic academia.[A258843] …
ASP-8731 is a novel BACH1 inhibitor that potentially induces fetal hemoglobin (HbF). Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.
Investigational
Matched Description: … Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093] …
SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
Investigational
Matched Description: … [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis …
Verekitug is under investigation in clinical trial NCT06164704 (A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps).
Investigational
Matched Description: … is under investigation in clinical trial NCT06164704 (A Study to Investigate the Efficacy and Safety of
Ruzinurad is under investigation in clinical trial NCT04956432 (A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout).
Investigational
Matched Description: … Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of
Pegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of Peg-hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis).
Investigational
Matched Description: … Pegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of
A naturally occurring amino acid in both eukaryotic and prokaryotic organisms. It is found in tRNAs and in the catalytic site of some enzymes. The genes for glutathione peroxidase and formate dehydrogenase contain the TGA codon, which codes for this amino acid. [PubChem]
Experimental
Matched Description: … It is found in tRNAs and in the catalytic site of some enzymes. …
Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.
Investigational
Matched Description: … Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques. …
Alkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile. AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.
Investigational
Matched Description: … AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from …
Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety. Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.
Withdrawn
Matched Description: … Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated …
EGT-301 is a gene therapy being investigated for Hunter Syndrome. It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome.
Investigational
Matched Description: … It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase …
Coagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX.[A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation.
Investigational
Matched Description: … [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing …
DYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1). It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.
Investigational
Matched Description: … It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable …
Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (Frα)-targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types).
Investigational
Matched Description: … investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of
Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With Er-positive, Her2-negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (Pionera Breast Cancer)).
Investigational
Matched Description: … Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of
Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Description: … It is an active metabolite of fluoxetine. …
The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs). It can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues that come with embryonic stem cells. The placental MSCs (pMSCs) are...
Investigational
Matched Description: … The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs) …
Elacytarabine is a fatty acid derivative of cytarabine, an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells. Elacytarabine is a patented...
Investigational
Matched Description: … Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. ... Elacytarabine is a patented new chemical entity of the nucleoside analog class, with improved biological …
The KBP-201 COVID-19 Vaccine was developed by British American Tobacco’s (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP). KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco plants for reproduction. Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals. As...
Investigational
Matched Description: … of KBP-COVID-19 vaccine in healthy patients (NCT04473690). ... As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity …
Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers. [PubChem]
Experimental
Matched Description: … Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. …
AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
Investigational
Matched Description: … AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. …
MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.
Investigational
Matched Description: … MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase …
TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
Investigational
Matched Description: … therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of
BIIB015 is a humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, anti-cripto, monoclonal antibody. It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.
Investigational
Matched Description: … It has been investigated for the treatment of subjects with relapsed or refractory solid tumours. …
Displaying drugs 8026 - 8050 of 8610 in total